SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Surface Oncology, Inc. (Nasdaq – SURF)

BALA CYNWYD – June 16, 2023 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Surface Oncology, Inc. (“Surface” or the “Company”) (Nasdaq – SURF) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to be acquired by Coherus BioSciences, Inc. (“Coherus”) (Nasdaq – CHRS). Under the terms of the Agreement, Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive certain Contingent Value Rights as part of the agreement.

The investigation concerns whether the Surface Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Coherus is paying too little for the Company.

If you own shares of Surface stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.